ellaOne

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
26-01-2024
Karakteristik produk Karakteristik produk (SPC)
26-01-2024

Bahan aktif:

ulipristal

Tersedia dari:

Laboratoire HRA Pharma

Kode ATC:

G03AD02

INN (Nama Internasional):

ulipristal acetate

Kelompok Terapi:

Sex hormones and modulators of the genital system, , Emergency contraceptives

Area terapi:

Contraception, Postcoital

Indikasi Terapi:

Emergency contraception within 120 hours (five days) of unprotected sexual intercourse or contraceptive failure.

Ringkasan produk:

Revision: 30

Status otorisasi:

Authorised

Tanggal Otorisasi:

2009-05-15

Selebaran informasi

                                37
B. PACKAGE LEAFLET
38
PACKAGE LEAFLET: INFORMATION FOR THE USER
ELLAONE 30 MG TABLET
Ulipristal acetate
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
Always take this medicine exactly as described in this leaflet or as
your pharmacist, doctor or other
healthcare professional has told you.
-
Keep this leaflet. You may need to read it again.
-
Ask your pharmacist if you need more information or advice.
-
If you get any side effects, talk to your pharmacist, doctor, or other
healthcare professional.
This includes any possible side effects not listed in this leaflet.
See section 4.
WHAT IS IN THIS LEAFLET
:
1.
What ellaOne is and what it is used for
2.
What you need to know before you take ellaOne
3.
How to take ellaOne
4.
Possible side effects
5.
How to store ellaOne
6.
Contents of the pack and other information
- Useful information about contraception
1.
WHAT ELLAONE IS AND WHAT IT IS USED FOR
ellaOne is an emergency contraceptive
ellaOne is a contraceptive intended to prevent pregnancy after
unprotected sex or if your contraceptive
method has failed. For example:
-
if you had sex without protection;
-
if your or your partner’s condom tore, slipped or came off, or if
you forgot to use one;
-
if you did not take your contraceptive pill as recommended.
You should take the tablet as soon as possible after sex, and within a
maximum of 5 days (120 hours).
This is because it is more effective if you take it as soon as
possible after unprotected sex.
This medicine is suitable for any woman of childbearing age, including
adolescents.
You can take the tablet at any time in the menstrual cycle.
ellaOne does not work if you are already pregnant
If your menstrual period is late, there is a possibility that you may
be pregnant. When your period is
late or when you have symptoms of pregnancy (heavy breasts, morning
sickness) you should consult a
doctor or other healthcare professional before taking the tablet.
If you have unprotected sex after taki
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
ellaOne 30 mg tablet
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains 30 mg ulipristal acetate.
Excipients with known effect
Each tablet contains 237 mg of lactose (as monohydrate).
For the full list of excipients, see section 6.1
3.
PHARMACEUTICAL FORM
Tablet
White to marble creamy, round curved tablet of 9 mm diameter engraved
with
_“еllа”_
on both sides.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Emergency contraception within 120 hours (5 days) of unprotected
sexual intercourse or contraceptive
failure.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Posology
The treatment consists of one tablet to be taken orally as soon as
possible, but no later than 120 hours
(5 days) after unprotected intercourse or contraceptive failure.
The tablet can be taken at any time during the menstrual cycle.
If vomiting occurs within 3 hours of the tablet intake, another tablet
should be taken.
If a woman’s menstrual period is late or in case of symptoms of
pregnancy, pregnancy should be
excluded before the tablet is administered.
_Special populations_
_ _
_Renal impairment_
No dose adjustment is necessary.
_Hepatic impairment _
In the absence of specific studies, no alternate dose recommendations
for ulipristal acetate can be
made.
_Severe hepatic impairment_
In the absence of specific studies, ulipristal acetate is not
recommended.
_Paediatric population _
There is no relevant use of ulipristal acetate for children of
prepubertal age in the indication
emergency contraception
_. _
3
Adolescents:
ulipristal acetate for emergency contraception is suitable for any
woman of child bearing age,
including adolescents. No differences in safety or efficacy have been
shown compared to adult women
aged 18 and older (see section 5.1).
Method of administration
Oral use.
The tablet can be taken with or without food.
4.3
CONTRAINDICATIONS
Hypersensitivity to the active substance or to any of the excipients
listed in section 6.1
4.4
SPECI
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 26-01-2024
Karakteristik produk Karakteristik produk Bulgar 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Bulgar 06-02-2015
Selebaran informasi Selebaran informasi Spanyol 26-01-2024
Karakteristik produk Karakteristik produk Spanyol 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Spanyol 06-02-2015
Selebaran informasi Selebaran informasi Cheska 26-01-2024
Karakteristik produk Karakteristik produk Cheska 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Cheska 06-02-2015
Selebaran informasi Selebaran informasi Dansk 26-01-2024
Karakteristik produk Karakteristik produk Dansk 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Dansk 06-02-2015
Selebaran informasi Selebaran informasi Jerman 26-01-2024
Karakteristik produk Karakteristik produk Jerman 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Jerman 06-02-2015
Selebaran informasi Selebaran informasi Esti 26-01-2024
Karakteristik produk Karakteristik produk Esti 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Esti 06-02-2015
Selebaran informasi Selebaran informasi Yunani 26-01-2024
Karakteristik produk Karakteristik produk Yunani 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Yunani 06-02-2015
Selebaran informasi Selebaran informasi Prancis 26-01-2024
Karakteristik produk Karakteristik produk Prancis 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Prancis 06-02-2015
Selebaran informasi Selebaran informasi Italia 26-01-2024
Karakteristik produk Karakteristik produk Italia 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Italia 06-02-2015
Selebaran informasi Selebaran informasi Latvi 26-01-2024
Karakteristik produk Karakteristik produk Latvi 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Latvi 06-02-2015
Selebaran informasi Selebaran informasi Lituavi 26-01-2024
Karakteristik produk Karakteristik produk Lituavi 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Lituavi 06-02-2015
Selebaran informasi Selebaran informasi Hungaria 26-01-2024
Karakteristik produk Karakteristik produk Hungaria 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Hungaria 06-02-2015
Selebaran informasi Selebaran informasi Malta 26-01-2024
Karakteristik produk Karakteristik produk Malta 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Malta 06-02-2015
Selebaran informasi Selebaran informasi Belanda 26-01-2024
Karakteristik produk Karakteristik produk Belanda 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Belanda 06-02-2015
Selebaran informasi Selebaran informasi Polski 26-01-2024
Karakteristik produk Karakteristik produk Polski 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Polski 06-02-2015
Selebaran informasi Selebaran informasi Portugis 26-01-2024
Karakteristik produk Karakteristik produk Portugis 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Portugis 06-02-2015
Selebaran informasi Selebaran informasi Rumania 26-01-2024
Karakteristik produk Karakteristik produk Rumania 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Rumania 06-02-2015
Selebaran informasi Selebaran informasi Slovak 26-01-2024
Karakteristik produk Karakteristik produk Slovak 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Slovak 06-02-2015
Selebaran informasi Selebaran informasi Sloven 26-01-2024
Karakteristik produk Karakteristik produk Sloven 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Sloven 06-02-2015
Selebaran informasi Selebaran informasi Suomi 26-01-2024
Karakteristik produk Karakteristik produk Suomi 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Suomi 06-02-2015
Selebaran informasi Selebaran informasi Swedia 26-01-2024
Karakteristik produk Karakteristik produk Swedia 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Swedia 06-02-2015
Selebaran informasi Selebaran informasi Norwegia 26-01-2024
Karakteristik produk Karakteristik produk Norwegia 26-01-2024
Selebaran informasi Selebaran informasi Islandia 26-01-2024
Karakteristik produk Karakteristik produk Islandia 26-01-2024
Selebaran informasi Selebaran informasi Kroasia 26-01-2024
Karakteristik produk Karakteristik produk Kroasia 26-01-2024
Laporan Penilaian publik Laporan Penilaian publik Kroasia 06-02-2015

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen